Engineered CAR-T Cells Show Promise for Prostate Cancer with Reduced Toxicity in Preclinical Studies
Scientists have developed a novel approach to CAR-T cell therapy that uses collagen-binding technology to localize treatment effects. The modified cells showed improved efficacy against prostate cancer tumors while significantly reducing toxic side effects typically associated with IL-12 therapies.
Breakthrough in Cancer Immunotherapy
Researchers have developed an innovative approach to CAR-T cell therapy that reportedly reduces toxicity while maintaining effectiveness against prostate cancer, according to a recent study published in Nature Biomedical Engineering. The new method involves engineering CAR-T cells with collagen-binding domains fused to interleukin-12 (IL-12), creating what sources describe as a more targeted and safer cancer treatment option.
